Rosen Law Firm Encourages Intellia Therapeutics Investors to Act Before Key Deadline in Securities Class Action

On February 15, 2025, Rosen Law Firm, a prominent global investor rights law firm, announced that a class action lawsuit has been filed on behalf of shareholders of Intellia Therapeutics, Inc. (NASDAQ: NTLA). This class action covers purchasers of Intellia securities from July 30, 2024, to January 8, 2025, a period known as the "Class Period." For those interested in leading the case, it is crucial to file a motion with the Court by April 14, 2025.

Those who bought Intellia securities during the specified time frame may be eligible for compensation, which can potentially be obtained without incurring any upfront costs, thanks to a contingency fee arrangement.

Next Steps for Investors

If you want to join the class action against Intellia, you can fill out a submission form on the Rosen Law Firm website or reach out directly to attorney Phillip Kim for further details. It's important to note that while a class action lawsuit is underway, it has not yet been certified, meaning you are not represented unless you select your own legal counsel.

Why Choose Rosen Law Firm?

Rosen Law Firm believes in the importance of hiring qualified counsel with a proven success record in handling leading roles in litigations. The firm focuses on securities class actions, shareholder derivative litigation, and has achieved substantial settlements over the years. They particularly note their track record of recovering hundreds of millions of dollars for investors, emphasizing their experience, resources, and recognition in the field of investor rights.

Details of the Case

The lawsuit highlights a lack of material information disclosed by Intellia's management regarding their Phase 1/2 study for NTLA-3001, which aims to treat alpha-1 antitrypsin deficiency-associated lung disease. Throughout the Class Period, statements from the defendants indicated a strong confidence in their research timelines, including plans to begin dosing patients in late 2024. However, they failed to reveal critical issues such as the diminishing demand for viral-based editing technologies, which have become less favorable compared to non-viral alternatives. As the true circumstances came to light, affected investors experienced significant financial losses.

As an investor, your ability to pursue a recovery doesn't hinge on serving as a lead plaintiff; you can stay a passive class member if you prefer.

Stay Informed

For ongoing updates regarding the case and investor rights, you may follow the Rosen Law Firm on their social media platforms.

Contact the Rosen Law Firm at the provided email and phone number for any inquiries related to this class action or investor assistance.

Attorney Advertising. Past outcomes do not guarantee future results.

Intellia, classaction, investors